Payments to be made upon achieving certain aggregate sales levels of the product detailed in the license agreement.

No definition available.

Name:	pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels
Namespace Prefix:	pdsb_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Payments to be made for development and first commercial sale milestones detailed in the license agreement.

+ References

No definition available.

+ Details

Name:	pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales
Namespace Prefix:	pdsb_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Royalty percentage paid on net sales of the product detailed in the license agreement.

+ References

No definition available.

+ Details

Name:	pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct
Namespace Prefix:	pdsb_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Period of time royalty is paid under license agreement after the first commercial sale of a product in a given country, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	pdsb_TermOfRoyaltyPayment
Namespace Prefix:	pdsb_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 53
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479589/842-20-55-53

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details

Name:	us-gaap_OperatingLeaseCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_OtherCommitmentsAxis=pdsb_MerckKGaALicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) - USD ($)	3 Months Ended		9 Months Ended
Commitments and Contingencies (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Commitments and Contingencies [Abstract]
Rent expense	$ 68,770	$ 106,171	$ 200,770	$ 359,373
Merck KGaA License Agreement [Member]
Commitments and Contingencies [Abstract]
Milestone payments for development and first commercial sales	11,000,000		$ 11,000,000
Royalty percentage paid on net sales of product			10.00%
Term of royalty payment			10 years
Merck KGaA License Agreement [Member] \| Maximum [Member]
Commitments and Contingencies [Abstract]
Milestone payments for aggregate sales levels of product	$ 105,000,000		$ 105,000,000